AI could help pathologists match cancer patients to the right treatments faster and more efficiently, study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Artificial intelligence could enhance how tumor samples are analyzed in the lab—significantly improving how doctors determine the best treatment for cancer patients, a study by researchers at the Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center, and other collaborators suggests. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login